Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:43:41.522Z.
Calculation as of: 2026-10-06T22:43:41.522Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Viridian Therapeutics, Inc.
Market Cap
$2.06B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.06B
EV/EBITDA Ratio
N/A
TTM Avg
238.50x
3Y Avg
123.46x
5Y Avg
123.46x
Market Cap
$2.05B
EV/EBITDA Ratio
65.14x
TTM Avg
96.19x
3Y Avg
628.91x
5Y Avg
603.99x
Market Cap
$2.02B
EV/EBITDA Ratio
N/A
TTM Avg
40.61x
3Y Avg
40.61x
5Y Avg
40.61x
Market Cap
$2.11B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
EV/EBITDA Ratio
N/A
TTM Avg
88.86x
3Y Avg
88.86x
5Y Avg
88.86x
Market Cap
$2.02B
EV/EBITDA Ratio
11.16x
TTM Avg
18.29x
3Y Avg
26.08x
5Y Avg
26.08x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 238.50x | 123.46x | 123.46x |
| Alvotech (ALVO)vs › | $2.08B | 41.97x | 33.53x | 180.18x | 180.18x |
| Vericel Corporation (VCEL)vs › | $2.05B | 65.14x | 96.19x | 628.91x | 603.99x |
| Progyny, Inc. (PGNY)vs › | $2.03B | 15.95x | 20.50x | 31.95x | 75.16x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 40.61x | 40.61x | 40.61x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A | N/A | N/A | N/A |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 88.86x | 88.86x | 88.86x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 11.16x | 18.29x | 26.08x | 26.08x |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
